{"id":33452,"date":"2025-05-14T17:54:10","date_gmt":"2025-05-14T09:54:10","guid":{"rendered":"https:\/\/flcube.com\/?p=33452"},"modified":"2025-05-14T17:54:11","modified_gmt":"2025-05-14T09:54:11","slug":"gsk-signs-deal-to-acquire-boston-pharmaceuticals-efimosfermin-alpha","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33452","title":{"rendered":"GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha"},"content":{"rendered":"\n

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK<\/a>) has entered into an agreement to acquire BP Asset IX, Inc., a subsidiary of US-based Boston Pharmaceuticals, a portfolio company of B-Flexion. The acquisition grants GSK access to efimosfermin alfa, a phase III-ready specialty medicine for treating and preventing the progression of steatotic liver disease (SLD).<\/p>\n\n\n\n

Deal Structure<\/strong>
Under the terms of the agreement, GSK will pay an upfront fee of USD 1.2 billion. Additionally, Boston Pharmaceuticals is eligible to receive up to USD 800 million in success-based milestone payments. GSK will also be responsible for milestone payments and tiered royalties to Novartis Pharma AG for efimosfermin.<\/p>\n\n\n\n

Drug Overview<\/strong>
Efimosfermin alfa is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog designed to address key metabolic pathways. It aims to reduce liver fat accumulation, alleviate liver inflammation, and reverse liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). The drug is currently in clinical trials for moderate to severe fibrosis, including cirrhosis, and is not yet approved for prescription.<\/p>\n\n\n\n

Strategic Rationale<\/strong>
Efimosfermin’s direct antifibrotic mechanism and GSK’s expertise in human genetics and disease phenotyping position the drug to address advanced stages of SLD. GSK also sees potential in combining efimosfermin with its siRNA therapeutic GSK\u2019990, currently in development for other SLD patient subsets.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP…<\/p>\n","protected":false},"author":1,"featured_media":33454,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4071,278,184,914],"class_list":["post-33452","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-boston-pharmaceuticals","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"\nGSK Signs Deal to Acquire Boston Pharmaceuticals' Efimosfermin Alpha - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP Asset IX, Inc., a subsidiary of US-based Boston Pharmaceuticals, a portfolio company of B-Flexion. The acquisition grants GSK access to efimosfermin alfa, a phase III-ready specialty medicine for treating and preventing the progression of steatotic liver disease (SLD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33452\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Signs Deal to Acquire Boston Pharmaceuticals' Efimosfermin Alpha\" \/>\n<meta property=\"og:description\" content=\"UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP Asset IX, Inc., a subsidiary of US-based Boston Pharmaceuticals, a portfolio company of B-Flexion. The acquisition grants GSK access to efimosfermin alfa, a phase III-ready specialty medicine for treating and preventing the progression of steatotic liver disease (SLD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33452\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T09:54:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-14T09:54:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1421.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha\",\"datePublished\":\"2025-05-14T09:54:10+00:00\",\"dateModified\":\"2025-05-14T09:54:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452\"},\"wordCount\":222,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1421.webp\",\"keywords\":[\"Boston Pharmaceuticals\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33452#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33452\",\"name\":\"GSK Signs Deal to Acquire Boston Pharmaceuticals' Efimosfermin Alpha - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1421.webp\",\"datePublished\":\"2025-05-14T09:54:10+00:00\",\"dateModified\":\"2025-05-14T09:54:11+00:00\",\"description\":\"UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP Asset IX, Inc., a subsidiary of US-based Boston Pharmaceuticals, a portfolio company of B-Flexion. The acquisition grants GSK access to efimosfermin alfa, a phase III-ready specialty medicine for treating and preventing the progression of steatotic liver disease (SLD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33452\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1421.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1421.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Signs Deal to Acquire Boston Pharmaceuticals' Efimosfermin Alpha\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33452#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Signs Deal to Acquire Boston Pharmaceuticals' Efimosfermin Alpha - Insight, China's Pharmaceutical Industry","description":"UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP Asset IX, Inc., a subsidiary of US-based Boston Pharmaceuticals, a portfolio company of B-Flexion. The acquisition grants GSK access to efimosfermin alfa, a phase III-ready specialty medicine for treating and preventing the progression of steatotic liver disease (SLD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33452","og_locale":"en_US","og_type":"article","og_title":"GSK Signs Deal to Acquire Boston Pharmaceuticals' Efimosfermin Alpha","og_description":"UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP Asset IX, Inc., a subsidiary of US-based Boston Pharmaceuticals, a portfolio company of B-Flexion. The acquisition grants GSK access to efimosfermin alfa, a phase III-ready specialty medicine for treating and preventing the progression of steatotic liver disease (SLD).","og_url":"https:\/\/flcube.com\/?p=33452","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-14T09:54:10+00:00","article_modified_time":"2025-05-14T09:54:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1421.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33452#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33452"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha","datePublished":"2025-05-14T09:54:10+00:00","dateModified":"2025-05-14T09:54:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33452"},"wordCount":222,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33452#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1421.webp","keywords":["Boston Pharmaceuticals","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33452#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33452","url":"https:\/\/flcube.com\/?p=33452","name":"GSK Signs Deal to Acquire Boston Pharmaceuticals' Efimosfermin Alpha - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33452#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33452#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1421.webp","datePublished":"2025-05-14T09:54:10+00:00","dateModified":"2025-05-14T09:54:11+00:00","description":"UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP Asset IX, Inc., a subsidiary of US-based Boston Pharmaceuticals, a portfolio company of B-Flexion. The acquisition grants GSK access to efimosfermin alfa, a phase III-ready specialty medicine for treating and preventing the progression of steatotic liver disease (SLD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33452#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33452"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33452#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1421.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1421.webp","width":1080,"height":608,"caption":"GSK Signs Deal to Acquire Boston Pharmaceuticals' Efimosfermin Alpha"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33452#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1421.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33452"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33452\/revisions"}],"predecessor-version":[{"id":33455,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33452\/revisions\/33455"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33454"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}